Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis-Reference-Cited by-同舟云学术

Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis

Published:2019-01-31 Issue:4 Volume:94 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Taher Ali T.¹^ORCID,Origa Raffaella²^ORCID,Perrotta Silverio³,Kouraklis Alexandra⁴,Belhoul Khawla⁵,Huang Vicky⁶,Han Jackie⁶,Bruederle Andreas⁷,Bobbili Priyanka⁸,Duh Mei Sheng⁸^ORCID,Porter John B.⁹

Affiliation:

1. Department of Internal Medicine American University of Beirut Medical Center Beirut Lebanon

2. Ospedale Pediatrico Microcitemico ‘A Cao’ University of Cagliari Cagliari Italy

3. Dipartimento della Donna, del Bambino e della Chirurgia Generale e Specialistica Universita degli Studi della Campania ‘Luigi Vanvitelli’ Naples Italy

4. Hematology Division, Department of Internal Medicine University of Patras Medical School Patras Greece

5. Dubai Thalassemia Center, Dubai Health Authority Thalassemia Center Dubai United Arab Emirates

6. Novartis Pharmaceuticals Corporation East Hanover New Jersey

7. Novartis Pharma AG Basel Switzerland

8. Analysis Group Boston Massachusetts

9. Department of Haematology University College London London United Kingdom

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25408

Reference6 articles.

1. Novartis Pharmaceuticals.EXJADE® (deferasirox) US Prescribing Information.2018.https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/exjade.pdf.

2. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome

3. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia

4. Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

5. New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Challenges with Iron Chelation in Beta Thalassemia;Hematology/Oncology Clinics of North America;2023-04

2. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia;Cochrane Database of Systematic Reviews;2023-03-06

3. Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm , interventional phase 4 study ( MIMAS );American Journal of Hematology;2022-05-31

4. Drug safety in thalassemia: lessons from the present and directions for the future;Expert Opinion on Drug Safety;2021-05-04

5. Too much iron: A masked foe for leukemias;Blood Reviews;2020-01